Developments Alder BioPharma BLA for eptinezumab accepted by FDA Alder BioPharma (NASDAQ:ALDR) BLA application for eptinezumab, a monoclonal antibody for the prevention of migraines, has been accepted by the FDA. Administered intravenously, eptinezumab targets and suppresses... April 23, 2019